The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia

ABSTRACT

Introduction: A three-month injection of paliperidone palmitate (PP3M) has been gradually introduced in the market since 2015. Recently, and due to different reasons, there is an increase in the LAIAs prescription rates, including patients in early phases of psychotic disorders.

Areas covered: The following article provides an overview of the antipsychotic market before providing the reader with an overview of the efficacy and tolerability data of the 3-month paliperidone palmitate formulation for the treatment of schizophrenia. The authors take into account the current state of knowledge, as well as the needs not covered by other therapeutic tools at our disposal at this time.

Expert opinion: PP3M offers a substantially longer dosing interval than other options, which may be a potential advancement to reduce nonadherence in some patients. Future research, both from randomized controlled trials and large pragmatic studies in real-world settings, will identify which subpopulation and disease stages may obtain greater benefit from this new formulation.

KEYWORDS:

• PP3M
• three-month paliperidone palmitate
• paliperidone
• InvegaTrinza
• Trevicta
• schizophrenia
• psychosis
• long-acting injectable antipsychotics
• adherence

Declaration of interest

M Bioque has been a consultant for, received honoraria from and/or been on the speakers/advisory board of Adamed, Ferrer, Janssen-Cilag, Lundbeck, Otsuka, and Pfizer Inc. M Bernardo has been a consultant for, received grant/research support and honoraria for serving on the advisory board or as a speaker from ABBiotics, Adamed, Angelini, Casen, Eli Lilly and Company, Janssen-Cilag, Lundbeck, Otsuka, Takeda, Somatics and has obtained research funding from the Ministry of Education, Culture and Sport, the Spanish Ministry of Economy, Industry and Competitiveness (CIBERSAM), from the Government of Catalonia, Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2017SGR1355) and the Foundation European Group for Research In Schizophrenia (EGRIS). He has also received grant support from the 7th Framework Program of the European Union. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This manuscript was not funded.